HOME >> BIOLOGY >> NEWS
Gene therapy study shows safety and statistically significant improvement in Parkinson's disease

FORT LEE, NJ (June 21, 2007) -- Neurologix, Inc. (OTC Bulletin Board: NRGX) today announced the publication in the June 23 issue of the journal The Lancet of positive results from the first ever gene therapy trial for Parkinsons disease and the first report of direct gene transfer into a patients own brain cells for any adult neurodegenerative disease.

The open label Phase 1 study, conducted in 12 patients with advanced Parkinsons disease demonstrated both a lack of adverse events related to the gene therapy procedure and statistically significant improvements from baseline in both clinical symptoms and abnormal brain metabolism (as measured by positron emission tomography, or PET scanning). Although all patients had symptoms on both sides of the body, the procedure was performed on only one side of the brain, enabling the untreated side to serve as a study control. The reported improvements were observed primarily on the treated side of the body beginning three months after the gene therapy procedure and persisted through the 12 months formal study period.

Neurologix sponsored the study as part of its ongoing efforts to develop this and other gene therapy approaches to the treatment of neurodegenerative and metabolic diseases. Principal investigators Michael G. Kaplitt, MD, PhD, and Matthew J. During, MD, PhD, performed the procedures at NewYork-Presbyterian Hospital/Weill Cornell Medical Center. Andrew Feigin, MD and David Eidelberg, MD of the Feinstein Institute for Medical Research, North Shore-Long Island Jewish Health System performed the clinical evaluations and the PET scans. Neurologix scientists were also co-investigators in the study.

This ground-breaking study represents not only an encouraging first step in the development of a promising new approach to Parkinsons disease therapy, but also provides a platform to translate a variety of new gene therapy agents into human clinical trials for many devastating brain disorder
'"/>

Contact: Joan Kureczka
JKureczka@comcast.net
415-821-2413
Kureczka/Martin Associates
21-Jun-2007


Page: 1 2 3 4

Related biology news :

1. Testosterone replacement therapy: How safe for aging men?
2. Progesterone therapy and preterm birth: More evidence helps identify women who can benefit
3. Aggressive therapy best for certain AML patients
4. Under magnetic force, nanoparticles may deliver gene therapy
5. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
6. Stem cell therapy rescues motor neurons in ALS model
7. Study identifies new gene therapy tools for inherited blindness
8. Breast cancer and hormone therapy -- A looking-glass mirror?
9. Radiation therapy combined with microsurgery shows promise for curing injured spinal cord
10. Nodal status is best predictor of outcome after neoadjuvant therapy for esophageal cancer
11. Scientists follow familiar TRAIL to new cancer therapy

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:7/31/2020)... SAN FRANCISCO (PRWEB) , ... July 30, 2020 ... ... Therapeutics’ maturing prescription digital therapeutics product portfolio with a near term focus on ... diverse biotech and pharma commercialization experience across multiple therapeutic areas and classes. As ...
(Date:7/10/2020)... ... , ... Today CJ BIO announced the first in a series of Food ... phenomenon that is revolutionizing ingredient mixes, nutritional content and flavor profiles across a range ... 13, 2020 at11:00 AM (CDT) during SHIFT20, the virtual edition of the IFT Annual ...
(Date:7/1/2020)... ... 01, 2020 , ... Cure Glioblastoma, a registered 501(c)(3) nonprofit ... aggressive adult brain cancer—announced today the appointments of its first Senior Fellows: John ... the organization’s initiatives and overall vision. , "Senior Fellows are more than advisors; ...
Breaking Biology News(10 mins):
(Date:8/3/2020)... ... ... Introducing Ardent Animal Health – MediVet Biologics rebrands company and positions its ... MediVet Biologics since its formation in 2016, the company is relaunching itself under the ... on its base of innovative therapies for osteoarthritis and cancer. , ...
(Date:7/31/2020)... ... July 29, 2020 , ... Diversified Technologies, Inc. has introduced ... configured to drive Klystrons, TWTs, IOTs, and magnetrons. , DTI Radar Transmitter ... in a push-pull configuration; yielding fast fall time for a capacitive load. These ...
(Date:7/31/2020)... TORONTO (PRWEB) , ... July 29, 2020 , ... eSource ... and inefficiencies. This webinar will cover the history of eSource, the reasons it did ... From EMR/EHR to wearables, to site source, the industry is moving towards capturing data ...
(Date:7/22/2020)... ... 22, 2020 , ... Join experts from Reed Tech , Gary Saner, ... a one hour live webinar on Thursday, August 13, 2020 at 11am ... and medical devices. Specifically, for medical devices, the NMPA has departments dealing with medical ...
Breaking Biology Technology:
Cached News: